Protara Therapeutics Accelerates Clinical Trials with Redesigned ADVANCED-3 and Cash Runway into 2028 — Protara Therapeutics, Inc.

Event summary

Protara expects to complete enrollment of the BCG-Unresponsive cohort in the ADVANCED-2 trial by Q4 2026.
The ADVANCED-3 trial is being redesigned to accelerate data collection in high-grade, high-risk NMIBC patients.
Interim results from the THRIVE-3 trial of IV Choline Chloride are expected in Q4 2026.
Protara reported $162 million in cash and investments as of June 30, 2026, sufficient to fund operations into 2028.

The big picture

Protara Therapeutics is positioning itself for multiple clinical and regulatory milestones in the coming quarters, with a focus on expanding the use of TARA-002 beyond BCG-Unresponsive NMIBC. The company's cash position provides a buffer into 2028, but its success will hinge on executing across its pipeline while navigating FDA interactions for both TARA-002 and IV Choline Chloride.

What we're watching

Regulatory Strategy: Whether the redesigned ADVANCED-3 trial will expedite FDA approval for TARA-002 in broader NMIBC patient populations.
Execution Risk: The pace at which Protara can complete enrollment and report interim results across its key trials by year-end 2026.
Financial Sustainability: How Protara will allocate its $162 million cash runway to support planned operations and potential future acquisitions or partnerships.